title: [Synthetic lethality as a functional tool in basic research and in anticancer therapy].
abstract: Nowadays, cancer and anticancer therapy are increasingly mentioned topics. Groups of researchers keep looking for a tool that will specifically and efficiently eliminate abnormal cells without any harm for the normal ones. Such method entails the reduction of therapy's side effects, thus also improving patient's recovery. Discovery of synthetic lethality has become a new hope to create effective, personalized therapy of cancer. Researchers noted that pairs of simultaneously mutated genes can lead to cell death, whereas each gene from that pair mutated individually does not result in cell lethality. Cancer cells accumulate numerous changes in their genetic material. By defining the pairs of genes interacting in cell pathways we are able to identify a potential anticancer therapy. It is believed that such a process has evolved to create cell resistance for a single gene mutation. Proper functioning of a pathway is not dependent on a single gene. Such a solution, however, also led to the evolution of multifactorial diseases such as cancer. Research techniques using iRNA, shRNA or small molecule libraries allow us to find genes that are connected in synthetic lethality interactions. Synthetic lethality may be applied not only as an anticancer therapy but also as a tool for identifying the functions of recently recognized genes. In addition, studying synthetic lethality broadens our understanding of the molecular mechanisms governing cancer cells, which should be helpful in designing highly effective personalized cancer therapies.
authors.affiliation: Katedra Genetyki Molekularnej Uniwersytetu Łódzkiego.
authors.forename: Monika
authors.initials: M
authors.lastname: Toma
authors.affiliation: Department of Microbiology and Immunology, and Fels Institute for Cancer Research, Temple University, School of Medicine, Philadelphia, PA, USA.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Skorski
authors.affiliation: Katedra Genetyki Molekularnej Uniwersytetu Łódzkiego.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Sliwiński
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D055808:Drug Discovery / Q000639:trends; D005804:Genes, Lethal; D006801:Humans; D009154:Mutation / Q000187:drug effects; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D011379:Prognosis; D034741:RNA, Small Interfering / Q000235:genetics / Q000627:therapeutic use*; D054852:Small Molecule Libraries / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering; D054852:Small Molecule Libraries